Spotlight On... Inspectors find big issues at API repackager in France; Vietnam invites Indian drugmakers to build plants; France's Amatsigroup buys Belgian's Q-Biologicals and more...

Sas Jarmat Laboratoire in Reventin Vaugris, France, has stopped its API repackaging operations and recalled all of its products after French inspectors discovered risks for cross-contamination at its facility. According to a report posted by the European Medicines Agency, the company was primarily selling APIs to compounding pharmacies in the Europe. French inspectors noted 21 deficiencies, including three they considered critical, including the possibilities of cross-contamination and the fact that the company was not testing products to see if they met specifications. In fact there were no batch records, they reported. Report

> Vietnam is asking Indian pharmaceutical manufacturers to build plants in that country. Story

> French CDMO Amatsigroup has acquired Belgian-based Q-Biologicals, which provides biologics process development and biomanufacturing services, from research to clinical phase. Report

> CMOs seem to be benefitting from pharma's M&A action. Report

Suggested Articles

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Continuing its expansion efforts, Japan’s Fujifilm will make a major investment in its U.S. gene therapy operation in Texas.